Josien C. Regelink

Amersfoort, UT, NL 
Amersfoort, UT, NL 

Overview

Josien Regelink practices practicing medicine in Amersfoort, Netherlands.

Their clinical expertise encompasses Multiple Myeloma, Hereditary Hyperekplexia, Leukemia, and Autoimmune Hemolytic Anemia.

They are actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 1 clinical trial.

Locations

Amersfoort, UT, Netherlands
Other Locations
Elisabeth TweeSteden Ziekenhuis
Tilburg, NB, Netherlands
Amsterdam, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3

19 Total Publications

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.
Journal: HemaSphere
Published: July 31, 2025

Frequently Asked Questions about Josien C. Regelink

Is Josien C. Regelink a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Josien C. Regelink is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Josien C. Regelink participate in research or clinical trials?

Yes. Josien C. Regelink has published 19 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Josien C. Regelink's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Regelink's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile